Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Ruxolitinib in advanced RAS mutant colorectal and pancreatic cancer
NCT04303403Phase 1Unknown
- Sponsor
- National Cancer Centre Singapore
- Start
- Jul 2018
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trametinib and ruxolitinib in colorectal cancer (CRC) and pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Centre Singapore. Primary endpoint: Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
trametinibruxolitinib
03
Conditions
colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04303403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303403.